ELND 004

Drug Profile

ELND 004

Alternative Names: ELND004

Latest Information Update: 20 Dec 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elan Corporation
  • Developer Perrigo
  • Class Small molecules
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 28 Feb 2009 Phase-I clinical trials in Autoimmune disorders in Europe (PO)
  • 29 Jul 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top